Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)
The objective of this study is to evaluate and compare the comfort of bromfenac or nepafenac following SLT.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Evaluation of Comfort With the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Xibrom (Bromfenac Ophthalmic Solution) 0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)|
- Tolerability of study medication [ Time Frame: 28 days ] [ Designated as safety issue: No ]
- Intraocular pressure changes [ Time Frame: 28 days ] [ Designated as safety issue: No ]
- Visual Acuity [ Time Frame: 28 days ] [ Designated as safety issue: No ]
|Study Start Date:||January 2009|
|Study Completion Date:||June 2009|
|Primary Completion Date:||June 2009 (Final data collection date for primary outcome measure)|
Active Comparator: 1
Xibrom: two times a day for seven days in the first eye.
Other Name: bromfenac
Active Comparator: 2
Nevanac: three times a day for seven days in the second eye.
Other Name: nepafenac
Open label, single armed, cross over controlled study to evaluate comfort and IOP (Intraocular Pressure) changes of specific NSAIDs post SLT. Patients (n= 25, total 50 eyes) scheduled to undergo bilateral Selective Laser Trabeculoplasty (SLT) will instill bromfenac in the first eye to undergo SLT, and the contra lateral eye will receive nepafenac.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00828477
|United States, Michigan|
|Coburn-Kleinfeldt Eye Clinic|
|3340 6 mile Rd Livonia, Michigan, United States, 48152|
|Principal Investigator:||Nate Kleinfeldt, M.D||Coburn-Kleinfeldt Eye Clinic|